RU486

A A Murphy, Ana A. Murphy, Murphy AA, Castellano PZ, Penny Ž. Castellano, P Z Castellano
Current opinion in obstetrics & gynecology · 1994 · vol. 6(3) , pp. 269–278 · doi:10.1097/00001703-199406000-00012 · PMID:8038415 · W2047982918
article OA: closed CC0 ⤵ 16 in-corpus citations
Full text JSON View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-13 ⓘ

RU486, an antiprogestin, has demonstrated efficacy in reducing pelvic pain and endometriosis scores, and decreasing uterine leiomyomata size, suggesting potential therapeutic applications.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by qwen3.7-flash, 2026-08-14 · read from full text ⓘ

This review examines the pharmacology of RU486 and its potential therapeutic applications for endometriosis and uterine leiomyomata. The authors highlight that antiprogestins like RU486 have provided new insights into progesterone receptor mechanisms while demonstrating clinical benefits such as reduced pelvic pain and lower endometriosis scores. Additionally, the text notes a significant decrease in the size of uterine fibroids following three months of treatment with the compound. This paper is centrally about endometriosis — specifically discussing how RU486 relieves associated pelvic pain and decreases disease severity scores alongside its effects on uterine leiomyomata.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

More than a decade after the serendipidous discovery of RU486, numerous antiprogestins have been synthesized and studied. Interest in how antiprogestins exert their antagonist effect has led to novel information about the molecular mechanisms of progesterone action. The pivotal role that progesterone plays in reproductive biology has led to research in many areas where a potential role for these compounds may be found in health and disease. RU486 has been shown to relieve pelvic pain associated with endometriosis and to decrease American Fertility Society endometriosis scores. Uterine leiomyomata show a significant reduction in size after administration of RU486 for 3 months. Although much research remains to be carried out, RU486 appears promising as alternative therapies for these diseases.
Full text 939 characters · extracted from oa-doi-fallback · click to expand
RU486 pharmacology and potential use in the treatment of endometriosis and leiomyomata uteri - Ana Alvarez Murphy - Penny Z. Castellano More than a decade after the serendipidous discovery of RU486, numerous antiprogestins have been synthesized and studied. Interest in how antiprogestins exert their antagonist effect has led to novel information about the molecular mechanisms of progesterone action. The pivotal role that progesterone plays in reproductive biology has led to research in many areas where a potential role for these compounds may be found in health and disease. RU486 has been shown to relieve pelvic pain associated with endometriosis and to decrease American Fertility Society endometriosis scores. Uterine leiomyomata show a significant reduction in size after administration of RU486 for 3 months. Although much research remains to be carried out, RU486 appears promising as alternative therapies for these diseases.

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

⚙ Ask this paper AI returns verbatim quotes from the full text · source: oa-doi-fallback ⓘ

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Condition tags

endometriosis

MeSH descriptors

Endometriosis Leiomyoma Mifepristone Uterine Neoplasms Endometriosis Endometrium Endometrium Female Humans Leiomyoma Mifepristone Mifepristone Progesterone Progesterone Uterine Neoplasms

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

Cited by (16)

Source provenance

europepmc
last seen: 2026-09-17T06:16:55.786923+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-05-13T22:11:24.284338+00:00
unpaywall
last seen: 2026-09-16T06:28:21.314993+00:00
License: CC0 · commercial use OK